Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B ...

Arbutus Biopharma Corporation announced promising data from a late-breaker poster presentation at the EASL Congress 2025, revealing that its treatment combining imdusiran, a RNAi therapeutic, with VTP ...

(Reuters) -Arbutus Biopharma on Tuesday sued U.S. drugmaker Pfizer Inc and its German partner BioNTech SE in a New Jersey district court, claiming their mRNA COVID-19 vaccines infringe five of Arbutus ...

Tourlite Capital Management, an investment management firm, released its third quarter 2024 investor letter, a copy of which can be downloaded here. Tourlite Fund, LP Founder Class returned 4.5% for ...

With hepatitis C virus starting to look like a conquered foe, attention is turning to the fight against chronic hepatitis B virus (HBV), and Vivek Ramaswamy’s Roivant has just put another sizable ...

Roivant Sciences and Moderna Therapeutics, two of the most highly-funded and controversial companies in the biotechnology world, are headed for a collision course over medical technology. On Monday, ...

Moderna stock fell 11% on Wednesday after the vaccine maker lost a patent fight against Arbutus Biopharma. Arbutus jumped 103% following the ruling as it could lead to royalty payments from Moderna.

It’s a David-and-Goliath fight between two unprofitable startups. Moderna Therapeutics is valued by its private investors at $5 billion, as it promises to create a new kind of medicine that will turn ...